R186
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.420
- APICAL_SURFACE+0.330
- KRAS_SIGNALING_DN+0.300
- WNT_BETA_CATENIN_SIGNALING+0.210
- PANCREAS_BETA_CELLS+0.130
- CHOLESTEROL_HOMEOSTASIS+0.110
- IL6_JAK_STAT3_SIGNALING+0.110
- INTERFERON_ALPHA_RESPONSE+0.110
- P53_PATHWAY+0.110
- TNFA_SIGNALING_VIA_NFKB+0.110
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- MYC_TARGETS_V1-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.390
- ANDROGEN_RESPONSE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
- E2F_TARGETS-0.320
- FATTY_ACID_METABOLISM-0.310
- MTORC1_SIGNALING-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- G2M_CHECKPOINT-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454742 | — | D | 0.852 |
| 2 | MDT-AP-1132 | Med | Medulloblastoma | 0.838 |
| 3 | SRR12696780 | — | — | 0.822 |
| 4 | SRR12202410 | — | — | 0.818 |
| 5 | SRR1489502 | GTEX | — | 0.812 |
| 6 | MDT-AP-0754 | Med | Medulloblastoma | 0.804 |
| 7 | R96 | — | — | 0.792 |
| 8 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.781 |
| 9 | MDT-AP-0123 | Med | Medulloblastoma | 0.777 |
| 10 | SRR12202413 | — | — | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |